Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years - Abstract

Dept. Pharmacology & Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands.

Dept. Urology, Medical University of Warsaw, Poland; Div. Obstetrics & Gynecology, Danderyt Hospital, Sweden; Urological Practice, Frankfurt, Germany; elbion, Leuven, Belgium.

 

 

To determine efficacy of the analgesic flupirtine in the treatment of overactive bladder syndrome in a proof-of-concept study.

Methods: Double-blind, double-dummy, three armed comparison of flupirtine extended release (400 mg/d, titrated to 600 mg/d), tolterodine extended release (4 mg/d) and placebo for 12 weeks.

When major elevations of liver enzymes (>3 times upper normal limit) were detected in several flupirtine-exposed patients, the study was prematurely discontinued. Based on study end data, hepatotoxicity was detected in 31% of patients receiving flupirtine for ≥6 weeks.

Unexpected frequent and relevant toxicity can occur when testing an established drug in a new indication. What is known about this subject Flupirtine has been on the market for about 30 years in several European countries as an analgesic. This use has not resulted in regulatory action concerning hepatotoxicity. What this study adds When used in a novel indication, hepatotoxicity was frequent with flupirtine, questioning the general assumption that the safety profile in one indication can be extrapolated to other indications.

Written by:
Michel MC, Radziszewski P, Falconer C, Marschall-Kehrel D, Blot K.   Are you the author?

Reference: Br J Clin Pharmacol. 2011 Nov 2. Epub ahead of print.
doi: 10.1111/j.1365-2125.2011.04138.x

PubMed Abstract
PMID: 22044433

UroToday.com Overactive Bladder (OAB) Section

 

email news signup